A Randomized, Blinded, Placebo-Controlled Study to Evaluate the Saftey and Efficacy of Oral LPCN 1154A in Women With Postpartum Depression
Latest Information Update: 05 Dec 2025
At a glance
- Drugs Brexanolone (Primary)
- Indications Postnatal depression
- Focus Registrational; Therapeutic Use
- Sponsors Lipocine
Most Recent Events
- 18 Nov 2025 According to a Lipocine media release, the study results are expected in the second quarter of 2026.
- 18 Nov 2025 According to a Lipocine media release, a meeting of the independent Data Safety Monitoring Board (DSMB) to review safety data from the study recommended that the trial to be continued as planned without modification.
- 18 Nov 2025 Interim results presented in the Lipocine media release.